Maria Serena Roca

5PUBLICATIONS
15CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Mar 28, 2026
Dual inhibition of mTOR and HSP90 enhances cisplatin efficacy and overcomes resistance in ovarian cancer.

Rita Lombardi, Laura Addi, Biagio Pucci

|Aug 01, 2025
Valproic acid improves the efficacy of oxaliplatin/fluoropyrimidine-based chemotherapy by targeting cancer stem cell via β-Catenin modulation in colorectal cancer.

Maria Serena Roca, Rita Lombardi, Cristina Testa

|Jul 17, 2024
The cross-talk between the macro and micro-environment in precursor lesions of pancreatic cancer leads to new and promising circulating biomarkers.

Carla Mottini, Francesca Romana Auciello, Isabella Manni

|Dec 17, 2020
HSP90 identified by a proteomic approach as druggable target to reverse platinum resistance in ovarian cancer.

Rita Lombardi, Maura Sonego, Biagio Pucci

|Jun 29, 2019
Implication for Cancer Stem Cells in Solid Cancer Chemo-Resistance: Promising Therapeutic Strategies Based on the Use of HDAC Inhibitors.

Maria Serena Roca, Elena Di Gennaro, Alfredo Budillon

Pageof 1

Frequent Collaborators

3 joint publications

Elena Di Gennaro

3 joint publications

Alfredo Budillon

2 joint publications

Gustavo Baldassarre

1 joint publications

Rita Lombardi